RT Journal Article
T1 Medicines use review service in community pharmacies in Spain: REVISA project.
A1 García-Agua Soler, Nuria
A1 Gómez-Bermúdez, Eugenia
A1 Baixauli-Fernández, Vicente J
A1 Bellver-Beltrán, Sara
A1 Velasco-Martínez, Javier
A1 García Ruiz, Antonio J
A1 Jódar-Sánchez, Francisco
K1 Adherence
K1 Community pharmacies
K1 Medicines use review
K1 Polypharmacy
K1 Willingness to pay
AB Background Community pharmacy services play an important role in controlling some factors related to medicine use and patients can benefit from these services to improve the adherence and knowledge of their medications, besides to reduce medicine-related problems. Objective The aim of the REVISA project is to carry out a study on preliminary implementation of the medicines use review service in Spanish community pharmacies. Setting Sixty-four community pharmacies from all regions of Spain. Method A preliminary implementation, cross-sectional multicentre study was conducted using a convenience sample of voluntary community pharmacies. A structured interview enabled to pharmacists to obtain a better understanding of patient's medicines use. Main outcome measure Medicines use review-related time and cost, satisfaction and willingness to pay. Results A total of 495 patients were enrolled. The mean age of the patients was 66.1 years, with the majority females (56.4%) and a mean consumption of 5.7 medicines. A total of 2811 medicines were evaluated and 550 referral recommendations were made (29.8% to Primary Care). The mean time employed by the pharmacists in the medicines use review service was 52.8 min (medicines use review-related cost of €17.27). Most patients expressed a high level of satisfaction with this service (98.5%) and a willingness to pay for it (84%). Conclusion Medicines use review service in community pharmacies in Spain can be delivered, that it appears to be acceptable to patients and that most patients said they would be willing to pay for it. This service may offer an opportunity to promote inter-professional collaboration between pharmacists and general practitioners.
YR 2020
FD 2020-09-29
LK http://hdl.handle.net/10668/16351
UL http://hdl.handle.net/10668/16351
LA en
DS RISalud
RD Apr 9, 2025